Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data

Mass General Brigham

Status: Completed

Conditions: Diabetes

Treatments: Drug: Glimepiride; Drug: Liraglutide

Study type: Observational

Funder types: Other

Identifiers

NCT05162183

2018P002966-DUP-LEAD2

Details and patient eligibility

About

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Full description

This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates through standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.

Enrollment: 3,474 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Type 2 Diabetes mellitus [0,0] days
• 3 or more recorded HbA1c values [-365, 0] days
• At least two dispensing claims for metformin [-180,0] days
• 1 or more recorded HbA1c values [-90,0] days
• Age between 18-80 [0,0] days

Exclusion criteria

• Cancer, malignant neoplasm, or MEN2 [-1,825,0] days
• Use of other anti-diabetic medications [-180,0] days
• Cirrhosis or Hepatic decompensation [-180,0] days
• Viral hepatitis B or C [-180,0] days
• Stage 5 CKD, ESRD, dialysis or renal transplant [-180,0] days
• MI or HF [-180,0] days
• Treatment with Anti-VEGFi or Photocoagulation [-180,0] days
• Hypertensive crisis or uncontrolled hypertension [-180,0] days
• Two diagnoses of hypoglycemia [-180,0] days
• Alcohol/drug abuse/dependence [-180,0] days
• Dementia and brain damages or non-compliance [-180,0] days
• Pregnancy [-180,0] days
• Type 1 DM, DKA, or other metabolic acidosis [-180,0] days
• Systemic corticosteroids [-90,0] days

Trial design

3,474 participants in 2 patient groups

Glimepiride

Description:

Reference Group

Treatment:

Drug: Glimepiride

Liraglutide

Description:

Exposure group

Treatment:

Drug: Liraglutide